Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Donald Notman sold 11,119 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the transaction, the insider now owns 193,444 shares in the company, valued at $1,510,797.64. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Donald Notman also recently made the following trade(s):
- On Friday, January 31st, Donald Notman sold 6,301 shares of Ocular Therapeutix stock. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84.
Ocular Therapeutix Stock Up 3.6 %
NASDAQ:OCUL traded up $0.27 during trading hours on Tuesday, hitting $7.82. 904,622 shares of the company traded hands, compared to its average volume of 904,992. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The company has a market cap of $1.23 billion, a PE ratio of -5.92 and a beta of 1.22. The firm’s 50-day simple moving average is $8.61 and its 200-day simple moving average is $9.02. Ocular Therapeutix, Inc. has a one year low of $4.06 and a one year high of $11.77.
Analyst Ratings Changes
Check Out Our Latest Analysis on Ocular Therapeutix
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 1,015 shares in the last quarter. Algert Global LLC bought a new position in Ocular Therapeutix in the 2nd quarter valued at $69,000. Capital Performance Advisors LLP purchased a new position in shares of Ocular Therapeutix in the 3rd quarter worth about $70,000. Palumbo Wealth Management LLC bought a new position in Ocular Therapeutix during the fourth quarter valued at about $100,000. Finally, Diversified Trust Co bought a new position in Ocular Therapeutix during the third quarter valued at about $106,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
See Also
- Five stocks we like better than Ocular Therapeutix
- What is the S&P/TSX Index?
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- How to buy stock: A step-by-step guide for beginners
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.